Article: Strategic and Technology Challenges in Bioprocessing
Mr. Mike May published an article in GEN News on 1st Dec about the strategic and technology challenges in bioprocessing. Mike approached our Head of Business Development Mr. Kassim Kolia who, among others, shared his insights on the topic:
“One of the most challenging aspects for a manufacturing, science, and technology (MSAT) team in gene-therapy manufacturing is downstream processing of viral vectors. You would expect yields to decrease more than 50% for this step. New technologies come into the market trying to eliminate this aspect, but it is not a quick fix—same goes for biologics manufacture as they are similar. These approaches are satisfactory, but they are not without serious challenges.”
Read the whole article here.